The Effect of Dosing Regimens on the Antimalarial Efficacy of Dihydroartemisinin-Piperaquine: A Pooled Analysis of Individual Patient Data

PLoS Medicine

Volumn 10, Issue 12, 2013, Pages 1-17

  Achan, Jane ^a   Adam, Ishag ^b   Arinaitwe, Emmanuel ^c   Ashley, Elizabeth A ^d,e   Awab, Ghulam Rahim ^e,f   Ba, Mamadou S ^g   Barnes, Karen I ^h   Bassat, Quique ^i,j   Borrmann, Steffen ^k,l   Bousema, Teun ^m,n   Dahal, Prabin ^o,p   D'Alessandro, Umberto ^m,q   Davis, Timothy M E ^r   Dondorp, Arjen M ^e,s   Dorsey, Grant ^t   Drakeley, Chris J ^m   Fanello, Caterina I ^e   Faye, Babacar ^g   Flegg, Jennifer A ^o,p   Gaye, Oumar ^g   Gething, Peter W ^u   González, Raquel ^i,j   Guerin, Philippe J ^o,p   Hay, Simon I ^u   Hien, Tran T ^v,w   Janssens, Bart ^x   Kamya, Moses R ^y   Karema, Corine ^z   Karunajeewa, Harin A ^r   Koné, Moussa ^aa   Lell, Bertrand ^ab,ac   Marsh, Kevin ^k,s   Mayxay, Mayfong ^ad,ae   Menéndez, Clara ^i,j   Mens, Petra F ^af,ag   Meremikwu, Martin ^ah,ai   Moreira, Clarissa ^o,p   Mueller, Ivo ^j,aj,ak   Nabasumba, Carolyn ^al   Nambozi, Michael ^am   Ndiaye, Jean Louis ^g   Newton, Paul N ^s,ad   Nguyen, Thuy Nhien ^w   Nosten, Francois ^d,e,s   Nsanzabana, Christian ^o,p   Omar, Sabah A ^an   Ouédraogo, Jean Bosco ^ao,ap   Penali, Louis K ^o   Pene, Mbaye ^g   Phyo, Aung Pyae ^d   Piola, Patrice ^aq   Price, Ric N ^s,ar   Sasithon, P ^as   Rosenthal, Philip J ^t   Same Ekobo, Albert ^at   Sawa, Patrick ^an   Schallig, Henk D F H ^af   Shekalaghe, Seif A ^au,av   Sibley, Carol Hopkins ^o,aw   Smith, Jeff ^o   Smithuis, Frank ^x,ax   Somé, Anyirékun Fabrice ^ao   Stepniewska, Kasia ^o,p   Talisuna, Ambrose O ^o,ay   Tarning, Joel ^e,p   Tjitra, Emiliana ^az   Tine, Roger C K ^g   Tinto, Halidou ^ao,ap   Valecha, Neena ^ba   Van Herp, Michel ^bb   Van Vugt, Michele ^bc   White, Nicholas J ^e,s   Woodrow, Charles J ^s,bd   Yavo, William ^aa,be   Yeka, Adoke ^a   Zongo, Issaka ^ao   more..

^a Uganda Malaria Surveillance Project   (Uganda)

^b UNIVERSITY OF KHARTOUM   (Sudan)

^c INFECTIOUS DISEASES RESEARCH COLLABORATION   (Uganda)

^d SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^e MAHIDOL UNIVERSITY   (Thailand)

^f Ministry of Public Health   (Afghanistan)

^g UNIVERSITÉ CHEIKH ANTA DIOP   (Senegal)

^h UNIVERSITY OF CAPE TOWN   (South Africa)

ⁱ Manhiça Health Research Center   (Mozambique)

^j CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^k KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^l UNIVERSITY OF HEIDELBERG   (Germany)

^m LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

ⁿ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^o WorldWide Antimalarial Resistance Network   (Kenya)

^p UNIVERSITY OF OXFORD   (United Kingdom)

^q INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^r UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^s CHURCHILL HOSPITAL   (United Kingdom)

^t UNIVERSITY OF CALIFORNIA   (United States)

^u UNIVERSITY OF OXFORD   (United Kingdom)

^v UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^w OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^x MÉDECINS SANS FRONTIÈRES   (Switzerland)

^y MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^z Ministry of Health   (Rwanda)

^aa Spatial Ecology and Epidemiology Group Department of Zoology University of Oxford Kenya Medical Research ^*  (Côte d’Ivoire)

^ab UNIVERSITY OF TÜBINGEN   (Germany)

^ac German Center for Infection Research   (Gabon)

^ad MAHOSOT HOSPITAL   (Laos)

^ae NATIONAL UNIVERSITY OF LAOS   (Laos)

^af ROYAL TROPICAL INSTITUTE   (Netherlands)

^ag ACADEMIC MEDICAL CENTER   (Netherlands)

^ah UNIVERSITY OF CALABAR   (Nigeria)

^ai Vector Group   (United Kingdom)

^aj PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

^ak WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^al EPICENTRE   (France)

^am TROPICAL DISEASES RESEARCH CENTRE   (Zambia)

^an International Centre for Insect Physiology and Ecology (ICIPE)   (Kenya)

^ao Institut de Recherche en Sciences de la Santé   (Burkina Faso)

^ap CENTRE MURAZ   (Burkina Faso)

^aq INSTITUT PASTEUR DE MADAGASCAR   (Madagascar)

^ar MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^as MAHIDOL UNIVERSITY   (Thailand)

^at Centre Hospitalier et Universitaire de Yaounde   (Cameroon)

^au KILIMANJARO CHRISTIAN MEDICAL CENTRE   (Tanzania)

^av IFAKARA HEALTH INSTITUTE   (Tanzania)

^aw UNIVERSITY OF WASHINGTON   (United States)

^ax Medical Action Myanmar   (Myanmar)

^ay KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^az NATIONAL INSTITUTE OF HEALTH RESEARCH AND DEVELOPMENT   (Indonesia)

^ba NATIONAL INSTITUTE OF MALARIA RESEARCH   (India)

^bb MÉDECINS SANS FRONTIÈRES   (Belgium)

^bc UNIVERSITY OF AMSTERDAM   (Netherlands)

^bd MAHIDOL OXFORD TROPICAL MEDICINE RESEARCH UNIT   (Thailand)

^be National Institute of Public Health   (Côte d’Ivoire)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTECAN; DIHYDROARTEMISININ; DIHYDROARTEMISININ PLUS PIPERAQUINE; PIPERAQUINE; UNCLASSIFIED DRUG;

ANEMIA; ANOREXIA; ANTIMALARIAL ACTIVITY; ARM DISEASE; ARTICLE; ASPIRATION PNEUMONIA; BODY WEIGHT; CLINICAL TRIAL (TOPIC); CONVULSION; DIARRHEA; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE TRANSMISSION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TREATMENT FAILURE; ENCEPHALITIS; FEVER; FOLLOW UP; GAMETOCYTE; GENOTYPE; HUMAN; MALARIA; MALARIA FALCIPARUM; META ANALYSIS (TOPIC); METHODOLOGY; MULTICENTER STUDY (TOPIC); PARASITE CLEARANCE; PARASITEMIA; POLYMERASE CHAIN REACTION; PYELONEPHRITIS; PYOMYOSITIS; RASH; RECURRENT DISEASE; REINFECTION; RISK FACTOR; SKIN DISEASE; SURVIVAL RATE; VOMITING;

EID: 84892892177     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001564     Document Type: Article

References (53)

1. Carneiro I, Roca-Feltrer A, Griffin JT, Smith L, Tanner M, et al. (2010) Age-patterns of malaria vary with severity, transmission intensity and seasonality in sub-Saharan Africa: a systematic review and pooled analysis. PLoS One 5: e8988 doi: 10.1371/journal.pone.0008988.
2. Price R, Luxemburger C, van Vugt M, Nosten F, Kham A, et al. (1998) Artesunate and mefloquine in the treatment of uncomplicated multidrug-resistant hyperparasitaemic falciparum malaria. Trans R Soc Trop Med Hyg 92: 207-211.
3. Sinclair D, Zani B, Donegan S, Olliaro P, Garner P, (2009) Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev pp. CD007483.
4. White NJ, (2008) The role of anti-malarial drugs in eliminating malaria. Malar J 7 (Suppl 1) (): S8.
5. WHO (2010) Guidelines for the treatment of malaria, second edition. 2012. Available: http://whqlibdoc.who.int/publications/2010/9789241547925_eng.pdf.
6. WHO (2012) World malaria report 2012. 2012. Available: http://www.who.int/malaria/publications/world_malaria_report_2012/wmr2012_full_report.pdf.
7. Barnes KI, Watkins WM, White NJ, (2008) Antimalarial dosing regimens and drug resistance. Trends Parasitol 24: 127-134.
8. White NJ, Pongtavornpinyo W, Maude RJ, Saralamba S, Aguas R, et al. (2009) Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance. Malar J 8: 253.
9. Sinclair D, Gogtay N, Brand F, Olliaro P, (2011) Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria. Cochrane Database Syst Rev pp. CD008492.
10. Zwang J, Ashley EA, Karema C, D'Alessandro U, Smithuis F, et al. (2009) Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis. PLoS One 4: e6358 doi:10.1371/journal.pone.0006358.
11. Bassat Q, Mulenga M, Tinto H, Piola P, Borrmann S, et al. (2009) Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoS One 4: e7871 doi:10.1371/journal.pone.0007871.
12. Four Artemisinin-Based Combinations Study G (2011) A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med 8: e1001119 doi:10.1371/journal.pmed.1001119.
13. Valecha N, Phyo AP, Mayxay M, Newton PN, Krudsood S, et al. (2010) An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia. PLoS One 5: e11880 doi:10.1371/journal.pone.0011880.
14. Davis TM, Hung TY, Sim IK, Karunajeewa HA, Ilett KF, (2005) Piperaquine: a resurgent antimalarial drug. Drugs 65: 75-87.
15. Tarning J, Zongo I, Some FA, Rouamba N, Parikh S, et al. (2012) Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clin Pharmacol Ther 91: 497-505.
16. WWARN (2013) Clinical trials review. Available: http://www.wwarn.org/resistance/malaria/literature/overview.
17. Adam I, Salah MT, Eltahir HG, Elhassan AH, Elmardi KA, et al. (2010) Dihydroartemisinin-piperaquine versus artemether-lumefantrine, in the treatment of uncomplicated Plasmodium falciparum malaria in central Sudan. Ann Trop Med Parasitol 104: 319-326.
18. Arinaitwe E, Sandison TG, Wanzira H, Kakuru A, Homsy J, et al. (2009) Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clin Infect Dis 49: 1629-1637.
19. Ashley EA, Krudsood S, Phaiphun L, Srivilairit S, McGready R, et al. (2004) Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. J Infect Dis 190: 1773-1782.
20. Ashley EA, McGready R, Hutagalung R, Phaiphun L, Slight T, et al. (2005) A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Clin Infect Dis 41: 425-432.
21. Borrmann S, Sasi P, Mwai L, Bashraheil M, Abdallah A, et al. (2011) Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast. PLoS One 6: e26005 doi:10.1371/journal.pone.0026005.
22. Grande T, Bernasconi A, Erhart A, Gamboa D, Casapia M, et al. (2007) A randomised controlled trial to assess the efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Peru. PLoS One 2: e1101 doi:10.1371/journal.pone.0001101.
23. Hasugian AR, Purba HL, Kenangalem E, Wuwung RM, Ebsworth EP, et al. (2007) Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin Infect Dis 44: 1067-1074.
24. Janssens B, van Herp M, Goubert L, Chan S, Uong S, et al. (2007) A randomized open study to assess the efficacy and tolerability of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia. Trop Med Int Heal 12: 251-259.
25. Kamya MR, Yeka A, Birwa H, Lugemwa M, Rwakimari JB, et al. (2007) Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials 2: e20 doi:10.1371/journal.pctr.0020020.
26. Karema C, Fanello CI, van Overmeir C, van Geertruyden JP, van Doren W, et al. (2006) Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. Trans R Soc Trop Med Hyg 100: 1105-1111.
27. Karunajeewa HA, Mueller I, Senn M, Lin E, Law I, et al. (2008) A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med 359: 2545-2557.
28. Mayxay M, Thongpraseuth V, Khanthavong M, Lindegardh N, Barends M, et al. (2006) An open, randomized comparison of artesunate plus mefloquine vs. dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in the Lao People's Democratic Republic (Laos). Trop Med Int Heal 11: 1157-1165.
29. Mens PF, Sawa P, van Amsterdam SM, Versteeg I, Omar SA, et al. (2008) A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya. Malar J 7: 237.
30. Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung RM, et al. (2007) Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet 369: 757-765.
31. Sawa P, Shekalaghe SA, Drakeley CJ, Sutherland CJ, Mweresa CK, et al. (2013) Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial. J Infect Dis 207: 1637-1645.
32. Smithuis F, Kyaw MK, Phe O, Aye KZ, Htet L, et al. (2006) Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Lancet 367: 2075-2085.
33. Smithuis F, Kyaw MK, Phe O, Win T, Aung PP, et al. (2010) Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis 10: 673-681.
34. Tran TH, Nguyen TT, Nguyen HP, Boni MF, Ngo VT, et al. (2012) In vivo susceptibility of Plasmodium falciparum to artesunate in Binh Phuoc Province, Vietnam. Malar J 11: 355.
35. Yavo W, Faye B, Kuete T, Djohan V, Oga SA, et al. (2011) Multicentric assessment of the efficacy and tolerability of dihydroartemisinin-piperaquine compared to artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa. Malar J 10: 198.
36. Yeka A, Dorsey G, Kamya MR, Talisuna A, Lugemwa M, et al. (2008) Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS One 3: e2390 doi:10.1371/journal.pone.0002390.
37. Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Sere Y, et al. (2007) Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Clin Infect Dis 45: 1453-1461.
38. WWARN (2012) Clinical Module: Data Management and Statistical Analysis Plan Version 1.2. Oxford. Available: http://www.wwarn.org/sites/default/files/ClinicalDMSAP.pdf.
39. Gething PW, Patil AP, Smith DL, Guerra CA, Elyazar IR, et al. (2011) A new world malaria map: Plasmodium falciparum endemicity in 2010. Malar J 10: 378.
40. WWARN (2012) Statistical Analysis Plan DHA-PQP Dose Impact Study Group. Version 1.9. Oxford. Available: http://www.wwarn.org/sites/default/files/DHA-PQPDoseImpactStudyGroupSAP.pdf.
41. Levin ML, (1953) The occurrence of lung cancer in man. Acta Unio Int Contra Cancrum 9: 531-541.
42. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, et al. (2009) Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361: 455-467.
43. Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, et al. (2012) Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 379: 1960-1966.
44. Leang R, Barrette A, Bouth DM, Menard D, Abdur R, et al. (2013) Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010. Antimicrob Agents Chemother 57: 818-826.
45. Price RN, Hasugian AR, Ratcliff A, Siswantoro H, Purba HL, et al. (2007) Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria. Antimicrob Agents Chemother 51: 4090-4097.
46. Nacher M, Carrara VI, Ashley E, McGready R, Hutagalung R, et al. (2004) Seasonal variation in hyperparasitaemia and gametocyte carriage in patients with Plasmodium falciparum malaria on the Thai-Burmese border. Trans R Soc Trop Med Hyg 98: 322-328.
47. White NJ, (2008) How antimalarial drug resistance affects post-treatment prophylaxis. Malar J 7: 9.
48. Barnes KI, Little F, Smith PJ, Evans A, Watkins WM, et al. (2006) Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin Pharmacol Ther 80: 582-596.
49. Creek DJ, Bigira V, McCormack S, Arinaitwe E, Wanzira H, et al. (2013) Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infants. J Infect Dis 207: 1646-1654.
50. Mwesigwa J, Parikh S, McGee B, German P, Drysdale T, et al. (2010) Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. Antimicrob Agents Chemother 54: 52-59.
51. Salman S, Page-Sharp M, Batty KT, Kose K, Griffin S, et al. (2012) Pharmacokinetic comparison of two piperaquine-containing artemisinin combination therapies in Papua New Guinean children with uncomplicated malaria. Antimicrob Agents Chemother 56: 3288-3297.
52. Tran TH, Dolecek C, Pham PM, Nguyen TD, Nguyen TT, et al. (2004) Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet 363: 18-22.
53. Stepniewska K, Ashley E, Lee SJ, Anstey N, Barnes KI, et al. (2010) In vivo parasitological measures of artemisinin susceptibility. J Infect Dis 201: 570-579.